Loading patent…
AssigneesOslo Universitetssykehus Hf, National and Kapodistrian University of Athens
InventorsGeorgios C. VOUGIOUKALAKIS, Georgios ROTAS, Theodossis THEODOSSIOU, Kristian BERG, Miguel Angel Miranda ALONSO, Mantas GRIGALAVICIUS, Somayeh EZZATPANAH, Tine Therese Henriksen RAABE
Estimating the term…
The invention provides endoplasmic reticulum-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents an endoplasmic reticulum-targeting moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.
An endoplasmic reticulum-targeted chemiluminescent agent for use in a method of photodynamic therapy.
An agent for use as claimed in any one of the preceding claims, wherein said chemiluminescent agent or chemiluminescent moiety is selected from the group consisting of luminol, isoluminol, lucigenin, acridinium esters, oxalate esters, and derivatives thereof.
An agent for use as claimed in any one of the preceding claims, wherein said photodynamic therapy comprises simultaneous or sequential use of a photosensitizer or a precursor thereof.
An agent as claimed in any one of the preceding claims for use in the photodynamic treatment of any disorder or abnormality of cells or tissues in an animal body (e.g. a human) which is responsive to photodynamic therapy.
Dependencies are inferred from the claim text.